Efferon Targets Pediatric Sepsis With CE-Marked Blood Purification Device

Sepsis is an acute inflammation triggered by infection, according to the report. When standard treatments such as antibiotics cannot stop the immune system’s overreaction, a patient’s blood must be filtered to remove deadly toxins. Efferon’s devices are absorbers of dangerous cytokines and toxins, the report said. The company says its technology lowers organ failure rates and significantly accelerates recovery in children.

Dima Romashin, Efferon’s co-founder and CEO, compared sepsis in the body to a fire. "In a fire, there are two things: the flame itself and smoke that it produces," he told TechCrunch. In sepsis, endotoxins are the flames and cytokines are the smoke, according to Romashin. Unlike other devices on the market, Efferon has developed a mechanism that can absorb both at once, he said.

Although Efferon makes absorbers for adults, its pediatric device, Efferon NEO, is proving especially effective, according to the report. Children have a significantly lower circulating blood volume, so they require medical devices engineered specifically for their physiology, Romashin told TechCrunch. The company says Efferon NEO is the first multimodal blood purification device specifically engineered for pediatric sepsis.

Efferon NEO is used in intensive care units across 30 countries, including European hospitals, Saudi Arabia and Thailand, TechCrunch reported. The company is now preparing to file for FDA approval and is on track to hit $2 million in annualized revenue by the end of 2026.

The startup’s technology was originally developed by scientists at Moscow State University, including co-founder Ivan Bessonov, according to TechCrunch. Romashin, a serial entrepreneur, stepped in earlier this year as CEO to help commercialize it. He acknowledged that Efferon is not growing at the breakneck pace of today’s AI startups, but he said true success for the company is measured by every child who gets to go home.

Editor's Summary Efferon NEO, a pediatric blood purification device from startup Efferon, has received CE marking and is used in 30 countries, according to TechCrunch. The company is preparing an FDA filing and targets $2 million in annualized revenue by the end of 2026. The device is designed to absorb both endotoxins and cytokines in children with sepsis, a condition that takes about 3 million children under five each year.